You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 45 No. 1, January 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Controlled Pilot Trial of Monthly Intravenous Cyclophosphamide in Multiple Sclerosis

James M. Killian, MD; Robert B. Bressler, MD; Richard M. Armstrong, MD; David P. Huston, MD

Arch Neurol. 1988;45(1):27-30.


Abstract

• Monthly intravenous cyclophosphamide treatment was compared with placebo treatment for one year in a controlled trial of 14 patients with relapsing/remitting multiple sclerosis. Eight patients received placebo and six patients received cyclophosphamide. The cyclophosphamide group showed a definite trend to have less frequent and less prolonged episodes than the placebo group. When each group served as their own controls, the cyclophosphamide group had a significant decrease in episodes while the placebo group did not. When the placebo group was then given cyclophosphamide, they also had a significant decrease in episodes. When all patients who were receiving cyclophosphamide were combined for analysis, the decrease in episodes was even more evident. Complications were minimal. These results suggest that monthly intravenous doses of cyclophosphamide may influence the frequency and duration of episodes of relapsing/remitting multiple sclerosis.



Author Affiliations

From the Departments of Neurology (Drs Killian and Armstrong), Medicine (Drs Bressler and Huston), and Microbiology and Immunology (Dr Huston), Baylor College of Medicine and the Methodist Hospital, Houston.


Footnotes

Accepted for publication Sept 18, 1987.

Reprint requests to the Methodist Hospital, Neurosensory Center, MS NB 302, 6501 Fannin, Houston, TX 77030 (Dr Killian).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Krishnan et al.
Arch Neurol 2008;65:1044-1051.
ABSTRACT | FULL TEXT  

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT  

Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?
Bryant et al.
J. Neurol. Neurosurg. Psychiatry 2001;70:574-579.
ABSTRACT | FULL TEXT  

Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT  

Side-effects of intravenous cyclophosphamide pulse therapy
Martin et al.
Lupus 1997;6:254-257.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.